Congenital lipoid adrenal hyperplasia (CLAH) is an autosomal recessive disorder characterized by impaired synthesis of all adrenal and gonadal steroid hormones. Recently, it was reported that mutations in the steroidogenic acute regulatory protein (StAR) gene cause CLAH. In the present study, we have analyzed the StAR gene of a Japanese patient with CLAH. PCR amplification and subsequent nucleotide sequencing of the StAR gene and those of her parents revealed that the patient has a compound heterozygous mutation of this gene. In one allele, an undescribed G to C transversion in codon 217, which occurred at the last base of exon 5 and thus altered the splice donor site sequence, apparently resulted in a substitution of Arg to Thr (AGG to ACG: R217T), and in the other allele, a C to T transition in codon 218 caused a substitution of Ala to Val (GCG to GTG: A218V), which has been previously shown to abolish StAR activity. In vitro expression analysis of an allelic minigene that consists of exons 4 -6 of the R217T mutant StAR gene showed that the G to C transversion in the splice donor site of exon 5 caused by the R217T mutation disrupts normal splicing, resulting in the complete skipping of exon 5, which alters the translation reading frame of exon 6, introduces a stop codon at amino acid position 174, and thus impairs the activity. A functional expression study of the R217T replacement mutant revealed that the mutant has no steroidogenesis-enhancing activity if the transcript of the R217T mutant allele is ever spliced normally and translated into the protein. From the genetic analysis of 50 healthy subjects, the novel R217T mutation was unlikely to be due to polymorphism. Together, these results indicate that this patient is a compound heterozygote for the mutation in the StAR gene (T217R and A218V) and that these mutations inactivate the StAR function and give rise to clinically manifest CLAH. (J Clin Endocrinol Metab 84: [3983][3984][3985][3986][3987] 1999) 
sists of exons 4 -6 of the R217T mutant StAR gene showed that the G to C transversion in the splice donor site of exon 5 caused by the R217T mutation disrupts normal splicing, resulting in the complete skipping of exon 5, which alters the translation reading frame of exon 6, introduces a stop codon at amino acid position 174, and thus impairs the activity. A functional expression study of the R217T replacement mutant revealed that the mutant has no steroidogenesis-enhancing activity if the transcript of the R217T mutant allele is ever spliced normally and translated into the protein. From the genetic analysis of 50 healthy subjects, the novel R217T mutation was unlikely to be due to polymorphism. Together, these results indicate that this patient is a compound heterozygote for the mutation in the StAR gene (T217R and A218V) and that these mutations inactivate the StAR function and give rise to clinically manifest CLAH. (J Clin Endocrinol Metab 84: 3983-3987, 1999) C ONGENITAL lipoid adrenal hyperplasia (CLAH), originally described by Prader and Siebenmann (1) , is the most severe form of congenital adrenal hyperplasia, leading to impaired production of all steroids, including glucocorticoids, mineralocorticoids, and sex steroids. This disorder is inherited as an autosomal recessive trait, and the affected individuals are all phenotypically female with a severe saltlosing syndrome that is fatal unless treated with steroid replacement therapy (2) . Because mitochondria from affected adrenal glands and gonads fail to convert cholesterol to pregnenolone, it had been postulated to be caused by a defect in the cholesterol side-chain cleavage enzyme, cytochrome P450scc (3, 4) . However, no mutations have been revealed in the P450scc gene in affected individuals, suggesting a defect in another undefined factor involving conversion of cholesterol to pregnenolone (5-7).
Steroidogenic acute regulatory protein (StAR) is a 30-kDa phosphorylated protein that rapidly appears in the mitochondria of steroidogenic cells after tropic stimulation and is required in the acute regulation of steroidogenesis (8) . It has recently been reported that mutations in the StAR gene cause CLAH (9) . To date, 15 different mutations in the StAR gene have been found in patients with CLAH from various ethnic groups (9 -18) .
In the present study we analyzed the StAR gene in a Japanese patient with CLAH and found that the patient has a novel compound heterozygous mutation in the StAR gene that inactivates its function.
Materials and Methods Patient
The patient is the first child of unrelated healthy Japanese parents. She was delivered at term after an unremarkable gestation through cesarean section because of breech presentation. Her birth weight was 2965 g. She was noticed to have hyperpigmentation, developed cyanosis and tachypnea soon after birth, and was referred to the neonatal intensive care unit of our university hospital. On physical examination she had remarkable pigmentation and normal female external genitalia with no ambiguity. The laboratory data are summarized in Table 1 . Blood sugar was low, and plasma cortisol remained low despite markedly elevated ACTH. The electrolyte values were initially normal, but the infant developed vomiting and mild salt loss at 2 days of age (131 mEq/L sodium and 5.0 mEq/L potassium). She was diagnosed as having adrenal insufficiency. She was treated with hydrocortisone and fludrocortisone and did well. During her infancy testis-like structures became palpable in the lower inguinal region bilaterally, and the karyotype obtained at 7 months of age was 46,XY. At 3 yr of age the bilateral inguinal gonads were re-moved, and histological examination of the gonads confirmed the presence of testicular tissue. From these results, she was diagnosed as having CLAH.
DNA amplification and sequence analysis of the StAR gene
The genomic DNAs of the patient and her parents were isolated from whole blood by proteinase K digestion and phenol/chloroform extraction after informed consent was obtained from each subject. DNA fragments that span each of seven exons of the human StAR gene were selectively amplified using PCR (19) . The oligonucleotide primers and PCR conditions were the same as described previously (16) . The amplified DNA fragments were purified by agarose gel electrophoresis and directly sequenced in both orientations by the dideoxynucleotide chain termination method (20) using a Thermo Sequenase kit (Amersham Pharmacia Biotech Japan Ltd., Tokyo, Japan).
Restriction analysis
The R217T mutation found in the patient and her mother, which creates a new restriction site for MaeII (Roche Molecular Biochemicals Gmbh, Mannheim, Germany), was confirmed by digestion PCR products with the restriction enzyme followed by electrophoresis on a 2% NuSieve GTG agarose gel (FMC Bioproducts, Rockland, ME).
In vitro expression of the StAR minigene
Exons 4 -6 of the mutant StAR gene carrying the R217T mutation and those of the normal StAR gene were amplified using the primer pair, S4-AS6, whose sequences were described previously (16) . The respective PCR products were subjected to cloning into a pCRII plasmid using a TA cloning kit (Invitrogen, San Diego, CA), and the nucleotide sequences were confirmed by the dideoxynucleotide chain termination method. The inserts were cleaved from the plasmid DNA with a restriction enzyme EcoRI (Nippon Gene Co. Ltd., Tokyo, Japan) and then ligated to an expression vector pRK 5 (Fig. 3A) . Four micrograms of the mutant or normal chimeric plasmid were transfected into COS-1 cells (RIKEN Cell Bank, Tsukuba, Japan) by the diethylaminoethyl-dextran method (21) . After 48 h, total ribonucleic acid (RNA) was extracted from the cells with an ISOGEN kit (Nippon Gene Co. Ltd., Tokyo, Japan). The first strand complementary DNA (cDNA) was synthesized in a 12.5-L reaction mixture containing 1 g total RNA, 0.5 g oligo(deoxythymidine) [12] [13] [14] [15] [16] [17] [18] , 0.8 mmol/L of each deoxy-NTP, 20 U ribonuclease inhibitor, 50 U TrueScript Reverse Transcriptase, and 1 ϫ reaction buffer, which was supplied by the manufacturer (Sawady Technology Co. Ltd., Tokyo, Japan). The resulting cDNA was subjected to PCR amplification with a sense primer in exon 4 corresponding to nucleotides 442-462 (RTS4, 5Ј-GACAAAGTGATGAGTAAAGTG-3Ј) and an antisense primer in exon 6 corresponding to the complement of 863-844 (RTAS6, 5Ј-TC-GATGCTGAGTAGCCACTG-3Ј; Fig. 3A ).
Functional expression of the R217T replacement mutant StAR
The wild-type StAR cDNA was amplified from a QUICK-Clone human adrenal gland cDNA (CLONTECH Laboratories, Inc., Palo Alto, CA) by PCR as reported previously (9), then ligated into the pCRII plasmid and sequenced. The R217T replacement was introduced in the wild-type StAR cDNA by the recombinant PCR method (22) . The wildtype and R217T replacement mutant StAR cDNAs were cleaved from the plasmid DNA with EcoRI, then ligated to the expression vector pRK 5, and designated pRK-StAR and pRK-R217T, respectively. One microgram of the pRK-StAR, the pRK-R217T, or the empty pRK 5 plasmid was cotransfected into COS-1 cells with 1 g F2 plasmid, which was constructed to express an NH 2 -P450scc-adrenodoxin reductase-adrenodoxin-COOH fusion protein (23) and was provided by Dr. Walter L. Miller (University of California, San Francisco, CA), as described above (21) . In addition, 1 g GH1-pRK, a human GH expression plasmid, was included in the transfection mixture and was used as an internal control for transfection efficiency. Forty-eight hours after transfection, the medium was collected for RIA of pregnenolone as described previously (24) .
Western blot analyses of mitochondrial fractions isolated from transfected COS-1 cells were carried out with a polyclonal antibody raised against recombinant human StAR, which was provided by Dr. Jerome F. Strauss III (University of Pennsylvania, Philadelphia, PA) (25) .
Results

Sequencing analysis of the StAR gene
The entire coding region of the StAR gene from the patient and her parents, including the exon-intron boundaries, was directly sequenced. The sequencing analysis of the patient revealed two heterozygous mutations (Fig. 1) . One mutation, designated R217T, was caused by a G to C transversion at the second nucleotide of codon 217 in exon 5, which apparently converted codon 217 (AGG) encoding Arg into ACG encoding Thr. The other, designated A218V, was caused by a C to T transition at the second nucleotide of codon 218 in exon 6, which changed codon 218 (GCG) encoding Ala to GTG encoding Val. The patient was also revealed to be homozygous for the D203A polymorphism (18) . No other mutations were found in any of the seven exons or the exon-intron boundaries of the StAR gene from the patient.
The sequencing analysis of her parents demonstrated that the father was heterozygous for the A218V mutation in the Study of the patient was performed at 0 -1 days of age.
FIG. 1. Partial nucleotide sequences of exon 5 (A) and exon 6 (B) of
the StAR gene from the patient. The patient had an apparent heterozygous missense mutation at codon 217 and a heterozygous missense mutation at codon 218.
StAR gene, whereas the mother was heterozygous for the R217T mutation (data not shown).
Restriction analysis
As shown in Fig. 2A , the R217T mutation creates a new recognition site for the restriction enzyme MaeII. Thus, amplification of a 405-bp fragment from exon 5 of the StAR gene containing this mutation followed by digestion with MaeII should yield 325-and 80-bp fragments, whereas the normal fragment remains uncut. As shown in Fig. 2B , restriction analysis of the patient and the mother gave a mixed digestion pattern, confirming their heterozygosity, whereas for the father only the undigested 405-bp fragment was seen, demonstrating that he does not have the R217T mutation. Fifty normal subjects had only the uncut 405-bp fragment.
Expression study of the StAR minigene
As shown in Fig. 3A , the R217T mutation destroys a consensus splice donor site sequence that exists at the exon 5-intron 5 boundary of the StAR gene. Therefore, we hypothesized that this mutation would cause abnormal splicing of the StAR gene. As adrenal or gonadal RNA of the patient was not available, we could not perform in vivo analysis of them to verify the hypothesis. Therefore, we made an in vitro expression study using the chimeric minigene system to analyze the transcription of the patient's R217T mutant StAR gene. We first constructed two chimeric minigenes that consisted of an expression vector pRK 5 vector and the R217T mutant or wild-type StAR gene, which spans exons 4 -6 (Fig.  3A) . After the respective minigenes were expressed in COS-1 cells, the splice site selection patterns for exons 4 -6 were assessed from the cDNA sizes that corresponded to the expressed messenger RNAs (mRNAs) by means of RT-PCR. If the mRNA splicing of the minigene proceeds normally, the RT-PCR amplification should yield a 422-bp product, whereas a 237-bp product would be amplified should the exon 5 be skipped (Fig. 3B) . As shown in Fig. 4A , the RT-PCR product of the chimeric minigene that included the wild-type StAR gene was 422 bp as expected, whereas the transcript of the R217T mutant minigene was 237 bp, 185 bp shorter than that of the wild-type product. We confirmed nucleotide sequences of these two 422-and 237-bp products by direct DNA sequencing analysis. The former consisted of exons 4, 5, and 6, whereas the latter consisted only of exons 4 and 6 (Fig. 4B) . This exon skipping altered the reading frame of exon 6, resulting in a premature stop codon (TAA) at codon 174, 57 bp downstream from the exon 4-exon 6 boundary.
Functional expression study of the R217T replacement mutant StAR
As the possibility that some mRNA was spliced normally in vivo could not be totally excluded because of unavailability of the patient's tissues, we built the construct expressing the R217T replacement mutant StAR and assessed its activity in transfected cells. The wild-type StAR efficiently facilitated the conversion of cholesterol to pregnenolone, but the R217T replacement mutant failed to enhance the conversion ( Table  2 ). Western blot analyses detected both the 37-kDa precursor and the 30-kDa mature form of the wild-type StAR and the R217T replacement mutant (data not shown).
Discussion
We identified a novel heterozygous mutation of the StAR gene in a Japanese patient affected with CLAH. Our patient had an undescribed R217T mutation in one allele and a previously reported A218V mutation in the other. The Q258X mutation of the StAR gene originally described by Lin et al. (9) is reported to account for about 70% of affected alleles in Japanese CLAH patients (11, 13) . Nakae et al. reported one Japanese CLAH patient who has a homozygous frameshift mutation, 246insG, but does not have the Q258X mutation (13). Our patient seems to be the second Japanese CLAH patient who does not carry the common Q258X mutation.
The G to C transversion at the last base of exon 5 could result in a splicing error and/or a substitution of Arg to Thr at codon 217. Therefore, we constructed not only the chimeric StAR minigene originating from the R217T mutant allele to assess the splice site selection patterns, but also the R217T replacement mutant StAR cDNA to estimate the functional consequences of the replacement. The expression study of the chimeric StAR minigene demonstrated that the transcript of the R217T mutant minigene lacked exon 5. The skipping of exon 5 in the StAR mRNA also results in a frame shift in exon 6 that would, if translated, introduce 18 novel amino   FIG. 2 . Detection of G to C substitution in codon 237 by MaeII digestion. A, A 405-bp fragment containing exon 5 was amplified using the primer pair, S5-AS5, and subjected to MaeII digestion. The R217T mutation generates a MaeII site producing two fragments of 325 and 80 bp. B, Electrophoretic patterns of the digested PCR products from the patient, her parents, and normal controls. The patient and the mother had 325-and 80-bp fragments as well as a undigested 405-bp product. The father and normal controls had only the undigested fragment. Ⅺ and E, Normal controls; , the father bearing a heterozygous A218V mutation; , the mother bearing a heterozygous R217T mutation; , the patient bearing the compound heterozygous mutation.
acids from codon 156 to 173 and a premature stop codon (TAA) at codon 174. It was demonstrated that the carboxylterminal 28 amino acids of the 285-amino acid StAR molecule is crucial for StAR activity by the functional expression study of the carboxyl-terminally truncated Q258X StAR mutant found in the CLAH patients. Thus, it is likely that the StAR mutant harboring exon 5 skipping caused by the R217T mutation would be functionally inactive even if translated. As expected, Tee et al. demonstrated that the mutant StAR mRNA lacking exon 5, which was caused by a T3 A transversion in intron 4, does not encode a stable, functionally active protein by the functional expression study (10) . The functional expression study of the R217T replacement mutant StAR demonstrated that the replacement of Arg to Thr at codon 217 resulted in total loss of the steroidogenesisenhancing activity. Thus, we conclude that the R217T mutation completely abolishes StAR activity as the result of either the aberrant splicing or the single amino acid substitution.
The other mutation detected in our patient was the missense mutation A218V. This mutation has been found in Caucasian and Japanese patients with CLAH (11, 13, 16) . The results of the expression study indicated that the A218V mutant shows minimal to null enhancement of the production of pregnenolone, although it can enter the mitochondria and be processed (11, 13) . Thus, it is highly likely that this mutation as well as the R217T mutation is the cause of CLAH in this patient.
Our patient showed no virilization of the external genitalia and developed adrenal insufficiency soon after birth, indi- Pregnenolene is shown as the mean Ϯ SD from four dishes.
cating that both testicular and adrenal steroidogenesis had been severely impaired when she was born. These findings are in good agreement with the results of the in vitro expression study demonstrating that the R217T and the A218V mutations cause total loss of StAR activity. It is noteworthy that the CLAH patient reported by Tee et al. (10) had a relatively late onset of symptoms (8 weeks of age). In this patient the T3 A transversion in intron 4 also caused the splicing error eliminating exon 5 in most of StAR mRNA, but some StAR mRNA was spliced normally; thus, StAR activity was presumably retained in part.
In conclusion, we have identified a novel genetic mutation in the StAR gene that results in CLAH and demonstrated that there exists some relationship between symptoms and StAR activity in CLAH patients.
